Empowered Funds
FDMT icon

Empowered Funds’s 4D Molecular Therapeutics FDMT Stock Holding History

Empowered Funds’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$352K Buy
+24,585
New +$320K ﹤0.01% 1968

Other funds holding FDMT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Empowered Funds's FDMT Position: Q3 2026 in Review

Empowered Funds opened a new position in 4D Molecular Therapeutics (FDMT) in Q3 2026: 24,585 shares worth $352K. The stake represents ﹤0.01% of the portfolio and ranks #1968 among its holdings.

110 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

  • Empowered Funds held 24,585 shares of 4D Molecular Therapeutics worth $352K as of Q3 2026.
  • 4D Molecular Therapeutics was a new Empowered Funds position in Q3 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Empowered Funds's portfolio in Q3 2026, its #1968 holding.
  • 110 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on Empowered Funds's 13F filing for Q3 2026, filed 13 Nov 2026.